Novel Short-Chain Quinones to Treat Vision Loss in a Rat Model of Diabetic Retinopathy.

ABSTRACT: Diabetic retinopathy (DR), one of the leading causes of blindness, is mainly diagnosed based on the vascular pathology of the disease. Current treatment options largely focus on this aspect with mostly insufficient therapeutic long-term efficacy. Mounting evidence implicates mitochondrial dysfunction and oxidative stress in the central etiology of DR. Consequently, drug candidates that aim at normalizing mitochondrial function could be an attractive therapeutic approach. This study compared the mitoprotective compounds, idebenone and elamipretide, side-by-side against two novel short-chain quinones (SCQs) in a rat model of DR. The model effectively mimicked type 2 diabetes over 21 weeks. During this period, visual acuity was monitored by measuring optokinetic response (OKR). Vision loss oc

SUBMITTER: Daniel A 

PROVIDER: S-EPMC7864174 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature